Bottom Line GLP-1 medications can stay in your system anywhere from a day to a week, depending on the type, dose, and individual factors like metabolism and organ function
Additionally, those with severe inflammatory bowel disease (Crohn's disease or ulcerative colitis) may experience worsening diarrhea, nausea, or abdominal cramping, since GLP-1 agonists already cause gastrointestinal side effects in 3050% of users
6 , 7 GLP1 RAs have been available as injectable formulations since exenatide received FDA approval in 2005 and as oral formulations since semaglutide was approved in 2019, 8 trials have demonstrated significant weight and HbA1c reduction benefits of GLP1 RA compared with standard of care in patients with type 2 diabetes at high cardiovascular risk
2007 Jul;30(7):1709-16
For women of all life stages - from early adulthood to perimenopause to postmenopause - Josie or Hers are excellent, affordable options
In the STEP 5 study, participants taking semaglutide lost an average of 15.2% of their body weight over two years, compared with 2.6% in the placebo group